Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

747 Features
Hypertension and cardiovascular disease

09 Nov 04

Over the past 30 years, numerous clinical trials evaluating a variety of different classes of drugs have conclusively shown the benefit of blood pressure reduction in reducing the risk of strokes and cardiovascular mortality. Moreover, such trials have clearly demonstrated that blood pressure is unlikely to be controlled with a single drug and often two or more therapies are required to achieve blood pressure targets.
CSF Medical

Double trouble hits Altana respiratory pipeline

05 Nov 04

Altana has announced the delay of its US application for Daxas until late 2005 due to clinical trial enrolment taking longer than originally anticipated. The news will be of further concern to the company's investors, coming on the back of the recent announcement that another of its respiratory drugs, Alvesco, failed to win full FDA approval.
Datamonitor

The changing face of prostate cancer

04 Nov 04

Prostate cancer is the most common male malignancy in Western countries. Surgery and radiological procedures for localized prostate cancer offer the possibility for curative treatment. Prostate cancer also represents one of the most lucrative oncology indications for the pharmaceutical industry because drug-based treatment is often very effective at delaying disease progression, even in advanced disease, which encourages high-volume and long-term usage. The use of hormonal manipulation for advan
LeadDiscovery

An insight into hepatocellular carcinoma

29 Oct 04

Hepatocellular carcinoma is the fifth commonest cancer worldwide with about one million new cases diagnosed annually. It is estimated that the incidence of hepatocellular carcinoma in the seven major pharma markets will continue to rise over the next decade. There is no gold standard therapy - the market is characterized by high levels of unmet need, large patient potential and high commercial potential. To mark the publication of its new feature "Hepatocellular Carcinoma" LeadDiscovery's analys
LeadDiscovery

Cardiovascular risks of HRT confirmed

22 Oct 04

Treatment with combined estrogen/progestin doubles the risk of VTE in post-menopausal women and for obese women the risk is even higher, a recent study showed. However millions of women no longer taking HRT remain at risk of osteoporosis, which presents a huge market opportunity for non-hormonal classes in treating and preventing osteoporosis.
Datamonitor

Accelerating Drug Development and Limiting Failure of Phase I and II Clinical Trials

22 Oct 04

Limitations in the ability to optimize dose modification within the clinical trial setting represents a serious bottleneck in the drug development process. This barrier increases development time, causes the unnecessary early termination of valuable candidates and adds up to $300 million/drug in costs. Petra Biotek are set to knock down these barriers through their computer-based Cycle Dose Modification system. The positive impact that this technology is expected to have on the clinical developm
LeadDiscovery

Nexium GP resource provides real value

19 Oct 04

Healthcare professionals in the UK are already experiencing the benefits of being able to view this extensive product and disease-based resource online at a time and place that is convinient to them
Colin Williams

Going OTC in the USA

18 Oct 04

The OTC market has become highly competitive for pharmaceutical manufacturers, particularly in the US, which is the largest consumer society in the world. There have been a number of consolidations and acquisitions in the pharmaceutical sector to help companies boost their presence in the OTC field.
Dr Faiz Kermani

Don’t be scared of Assessment Centres

15 Oct 04

Recruitment is a very inexact science – the statistics in favour of making the right decision based on the traditional interview alone are horrifyingly low (the percentage is in single figures). This is a fact that has really only been acknowledged in recent years and, as a result, organisations have looked for ways to improve the success rate of their selection choices.
Lydia Holder

Peripheral arterial disease (PAD): A Significant Opportunity for Interventional Therapies

15 Oct 04

Peripheral arterial disease (PAD), caused by systemic atherosclerosis, is vastly underappreciated despite its abysmal mortality rates. With 5 and 10-year rates of 30% and 50% respectively mortality due to PAD is greater than that caused by coronary artery disease and stroke and is exceeded only by colorectal cancer. Better use of the pharmacological and interventional treatments available would dramatically improve the lives of the millions of PAD patients while at the same time ballooning the r
LeadDiscovery

Flu season begins but a vaccine shortage awaits

14 Oct 04

The recent government suspension of the manufacturing license for major flu vaccine maker Chiron in the UK has left many countries facing a severe shortage in flu vaccine supply for the 2004-05 season. In the light of previous vaccine provision difficulties, Datamonitor's Laura Harris argues that, in the longer term, cell culture vaccines could resolve the annual flu vaccine quandary...
Datamonitor

Life after Vioxx - $2.5 billion up for grabs?

11 Oct 04

Last week, Merck & Co sent shockwaves through the pharmaceutical market with the announcement that it had voluntarily withdrawn its blockbuster arthritis drug Vioxx. Datamonitor's Adele Schulz examines the likely impact of this event, for the remainder of 2004 and beyond, on both Merck and its rivals...
Datamonitor

HIV infection - changes in epidemiology driving R&D development and increased market value

07 Oct 04

The demographics of HIV patients are shifting, with the average age of those infected with HIV ever increasing due to longer life expectancy and higher survival rates. However, with increasingly complex infections and drug resistance developing in long term patients, novel medications and new combinations are now being launched to continue the fight...
LeadDiscovery

Therapeutic activity of Bayer's BAY 43-9006 in renal cell carcinoma

05 Oct 04

Renal cell carcinoma (RCC) is a niche cancer that accounts for 2-3% of all solid tumors in the major pharmaceutical markets. Approximately 30,000 patients are diagnosed with the disease each year in the US and 12,000 patients die of the disease annually. The market is currently dominated by the cytokines, but there is significant interest among physicians in the potential of anti-angiogenics, particularly so since renal cell carcinomas are known to be well vascularized. Bayer's BAY 43-9006 is a
LeadDiscovery

COX-2 withdrawal - Therapeutic, R&D and pharmaceutical impact

01 Oct 04

As the dust settles on Merck's withdrawal of Vioxx's, LeadDiscovery investigates the impact that this will have on the treatment of pain, R&D activity directed towards the identification of new approaches, and on pharmaceutical sales relating to COX-2 inhibitors and related drug classes
LeadDiscovery

New molecular target identified for the prevention of Alzheimer's disease

30 Sep 04

The market for Alzheimer's therapy is expected to grow from 16 million patients to 21 million by 2010 in the seven major pharmaceutical markets. Alzheimer's disease market in the seven major markets is worth $4.7 billion and will increase to $6.1 billion by the year 2005 and $ 7.8 billion by the year 2010. The major unmet need in this market is for disease modification and disease prevention. Recent findings by British researchers showing that targeting the neuronal adaptor protein X11beta can r
LeadDiscovery

Improving levodopa-based complications to advance Parkinson's Disease therapies

29 Sep 04

The pharmaceutical market for the treatment of neurodegenerative disorders will grow by an unprecedented amount over the next ten years. The aging of the baby-boom generation, combined with new and improved treatments for neurodegenerative disorders such as Alzheimer's and Parkinson's disease will lead to an expansion of the already $30 billion neurodegenerative market. Despite the growth of generic products, Parkinson's disease drug revenues grew an impressive 17% across the seven major markets
LeadDiscovery

Unlocking China’s Pharma Potential

24 Sep 04

China is predicted to be a major pharmaceutical market in the future. However, like other emerging markets, there are a number of challenges that companies need to deal with in order to unlock its full potential.
Dr Faiz Kermani

Sankyo's angiotensin II receptor blocker (ARB) olmesartan medoxomil demonstrates antiinflammatory activity in hypertensive patients.

22 Sep 04

Earlier this year data was reported that Sankyo's angiotensin II receptor blocker (ARB) olmesartan medoxomil may offer improved anti-hypertensive activity when compared to other therapeutic agents within this highly competitive $31 billion market. More recently clinical data has appeared that shows olmesartan to have additional anti- inflammatory activity in hypertensive patients with vascular inflammation. This may confer additional therapeutic benefit since inflammation is an etiological compo
LeadDiscovery

Development of anti-CD154 monoclonal antibodies for the prevention of transplant rejection

21 Sep 04

The recent success of monoclonal antibody therapies such as Genentech's Rituxan and Johnson & Johnson's Remicade are driving further development of this field. MAb therapies brought in revenues of over $5.1 billion in 2003, a figure which should nearly triple over the next five years as new MAbs are launched and following the approval of new indications for MAbs already on the market. By 2008, MAbs should account for 32 percent of all revenue in the biotech market. One therapeutic antibody indic
LeadDiscovery

Fujisawa's FK-866 reduces the growth and vascularization of renal cell carcinomas and also tumor metastasic

21 Sep 04

Renal cell carcinoma (RCC) is a niche cancer that accounts for 2-3% of all solid tumors in the major pharmaceutical markets. Approximately 30,000 patients are diagnosed with the disease each year in the US and 12,000 patients die of the disease annually. The market is currently dominated by the cytokines, but there is significant interest among physicians in the potential of anti-angiogenics, particularly so since renal cell carcinomas are known to be well vascularized. Researchers have now show
LeadDiscovery

IL-27 as an exciting new target for cancer immunotherapy

21 Sep 04

In 2002 nearly 1,285,000 new cancer cases were diagnosed in the United States, and due to the lack of options for the treatment of advanced disease more than 550,000 Americans died of the disease. Immunotherapy represents an emerging approach to the treatment of cancer that promises high specificity with negligible side effects. This approach to cancer treatment commonly involves the stimulation of T cells and antibody production and the use of cytokines has been extensively studied. IL-12 has b
LeadDiscovery

Developing therapeutic agents for the treatment of early (premature) ejaculation

21 Sep 04

Early ejaculation represents a major market, and indeed in 18-65 year olds it represents the predominant sexual dysfunction, affecting at least 20% of men. The global annual market for the treatment of early ejaculation has been estimated at $4 billion. However due to the absence of readily available therapeutics fewer than 10% of patients seek treatment for early ejaculation. Successful pharmaceutical development in this field may therefore reap immense rewards. Drug development has however bee
LeadDiscovery

Berlex researchers develop lipoxin A4 (LXA4) mimics for the treatment of inflammation

21 Sep 04

Treatments for inflammatory diseases comprise a $20 billion market spanning diseases such as psoriasis, asthma, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Both the prostaglandins and the leukotrienes are involved in the initiation and maintenance of inflammatory responses however agents that center on these mediators have produced limited therapeutic efficacy in various inflammatory disease settings. Harnessing the properties of anti-inflammatory mediators such as l
LeadDiscovery

Advances in the development of corticotropin-releasing-hormone (CRH) receptor agonists as candidate analgesics

21 Sep 04

It has been estimated that 9% of the US population suffers from moderate to severe non-cancer-related pain. Acute pain resulting from conditions such as headache, muscle spasms, dental problems or following surgery, affects 90 million Americans every year and the development of analgesics represents a major pharmaceutical objective. A recent study has demonstrated the analgesic activity of corticotropin-releasing-hormone (CRH) and has shown that this activity is probably due to activity within t
LeadDiscovery

Emerging Drug Discovery Targets: 21st September

21 Sep 04

Emerging Drug Discovery Targets provides a regular summary of some of the most exciting breaking information recently featured by the pharmaceutical analysts, LeadDiscovery. Information includes editorials on recently published journal articles, selected press releases and "intelligence reports". This edition features an LXA4 mimic for the treatment of inflammation; IL-27 as a cancer immunotherapy; anti-CD154 for organ transplant; CRH agonists for the treatment of pain; and an effective therapy
LeadDiscovery

PharmaNews Bytes: Selected September press releases from the pharma/biotech sector

17 Sep 04

LeadDiscovery's intelligence service, DailyUpdates has evolved as a key tool to help all in the drug development sector keep track of breaking journal articles, press releases and pharmaceutical reports. Pharma NewsBytes features selected press releases recently featured on DailyUpdates and offers the reader a leisurely stroll through the past few weeks of activity from within the pharmaceutical industry.
LeadDiscovery

GlaxoSmithKline's IkappaB kinase 2 (IKK-2) inhibitor, TCPA-1 as a potential next generation disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis

15 Sep 04

The TNF blockers Enbrel (etanercept) and Remicade (infliximab), have contributed to a revolution in the treatment of rheumatoid arthritis. The drug development community is now expending considerable resources on developing next generation disease modifying antirheumatic drugs (DMARDs) with improved efficacy and safety as well as oral activity. GlaxoSmithKline's IkappaB kinase 2 (IKK-2) inhibitor, TCPA-1 has recently been developed and has shown considerable promise in early stage development.
LeadDiscovery

Patient compliance is a $30 billion complaint

13 Sep 04

We all forget to take medication from time to time, or maybe even don't bother to refill our prescriptions because we're feeling fine. However, the cumulative effect of all this is costing the pharmaceutical industry in excess of $30 billion a year. Datamonitor's Adele Schulz offers pharmaceutical companies some practical solutions to help stop the financial bleeding...
Datamonitor

Trials & Tribulations: Advances in the Development of Histone Deacetylase (HDAC) Inhibitors for the Treatment of Cancer

10 Sep 04

Histone deacetylase (HDAC) inhibitors, having received considerable R&D attention, are now being led through the clinic by SAHA which is currently in phase II development. A second HDAC inhibitor, Titan's Pivanex, has now been shown to be effective as a single agent therapeutic in patients with non-small cell lung cancer. Due to toxicity observed when used in combination with docetaxel, development for this indication has been terminated. Studies have however recently been initiated to investiga
LeadDiscovery

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.